PP405 (PP30) Nanoliquid

PP405 (PP30) is a novel, non-hormonal, topical small-molecule inhibitor of the mitochondrial pyruvate carrier (MPC), PP30 being a prodrug to JXL-069. Built from UCLA-originated metabolic-stem-cell research and licensed to Pelage Pharmaceuticals, PP405 selectively reawakens dormant hair follicle stem cells by shifting their energy use into glycolysis—thereby promoting hair growth. In a Phase 2a human trial, it demonstrated excellent tolerability, no systemic absorption, and hair density increases (≥20%) in ~31% of treated men after eight weeks, including growth in previously bald areas. Phase 3 trials are expected in 2026, with potential commercial availability by late-decade.

EON Biotech released a world premiere, first-in-class, special nanoliquid formulation.

The carrier solution is currently being patented.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.